The sodium phenylbutyrate market has seen significant growth in recent years owing to its usage in treating urea cycle disorders. Sodium phenylbutyrate is used as an alternative pathway for removing ammonia from the blood in patients suffering from urea cycle disorders which involve genetic defects that affect the body's ability to remove ammonia. It works by conjugating with glutamine to form phenylacetylglutamine which can then be excreted in the urine. This helps lower ammonia levels and prevent buildup which can cause neurological issues. The widespread application of sodium phenylbutyrate for managing urea cycle disorders like argininosuccinic aciduria and citrullinemia has boosted the market size considerably.
The Global Sodium Phenylbutyrate Market is estimated to be valued at US$ 2.22 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the sodium phenylbutyrate market are Halliburton Co., Hifi Engineering Inc., Silixa Ltd., Schlumberger Limited, Banweaver, Omnisens SA, Future Fibre Technologies Ltd., Baker Hughes, Inc., Qintiq Group PLC, and Fotech Solutions Ltd.
The growing incidences of urea cycle disorders worldwide has increased the demand for sodium phenylbutyrate significantly. According to stats, approximately 1 in 35,000 babies in the US are born with a urea cycle disorder annually, driving volume sales.
Major companies involved in sodium phenylbutyrate production have expanded their global presence with manufacturing and distribution networks across key regions. For instance, Horizon Therapeutics plc has marketing authorizations for sodium phenylbutyrate in over 30 countries thereby reaching more patients worldwide.
Market Drivers
The increasing R&D initiatives towards developing novel drug delivery systems for Sodium Phenylbutyrate Market Demand is a major market driver. Players are investing in formulations like delayed and extended release tablets and granules to improve medication adherence and reduce dosing frequency for better management of urea cycle disorders. This has augmented sodium phenylbutyrate demand greatly over the past decade.
The current geopolitical instability and conflicts around the world are negatively impacting the growth of the sodium phenylbutyrate market. Regions experiencing political turmoil and sanctions sees reduced economic activity hampering industry and commerce. This translates to lower demand for sodium phenylbutyrate used in pharmaceutical applications. Manufacturers in these regions face difficulties in procuring raw materials and exporting finished goods due to trade restrictions. They have to rely more on local resources pushing up production costs. This makes their products less competitive in the global market. Additionally, transportation and logistics within and across borders becomes challenging jeopardizing just-in-time deliveries. To overcome such challenges, companies will need to diversify their supplier and customer bases beyond politically volatile regions and forge new international partnerships. Adopting a multi-local or regionalized approach to manufacturing rather than relying on a few strategically important units can help mitigate political risks. Continuous monitoring of geopolitical issues and flexible contingency plans will also aid market players to proactively respond and minimize losses during times of instability.
The market for sodium phenylbutyrate is currently concentrated in North America and Western Europe owing to the high demand for orphan drugs in these developed markets. Countries like the United States, Germany, United Kingdom and France account for a major share of the overall sodium phenylbutyrate consumption driven by their sophisticated healthcare infrastructure and sizeable patient pools suffering from amino acid metabolism disorders. However, with greater economic prosperity and healthcare spending, the sodium phenylbutyrate market in Asian countries is emerging as the fastest growing regional segment. Nations such as China, Japan and South Korea are expected to significantly drive the future growth momentum in the Asia Pacific region attributed to their large populations and growing incidences of metabolic diseases. Rising medical tourism along with government initiatives to strengthen domestic pharmaceutical industries also make Asia an attractive market for global as well as local sodium phenylbutyrate manufacturers.
Among Asian countries, China accounts for the largest and fastest growing sodium phenylbutyrate market currently. This can be attributed to China's massive population base which is most prone to metabolic disorders combined with improved access to healthcare facilities across the country in recent times. Rapid economic development and increased per capita incomes have enabled the Chinese to spend more on medications and premium drugs like sodium phenylbutyrate. Furthermore, the Chinese government is strongly supporting the growth of local pharmaceutical manufacturing through subsidies and trade policies to reduce reliance on imports and achieve self-sufficiency in drug production. Domestic Chinese manufacturers of sodium phenylbutyrate have emerged as serious low cost competitors to multinational companies. This makes China a strategic priority market for all players in this industry.
Get more insights on Sodium Phenylbutyrate Market
Also read related article on Spinal Cord Injury Therapeutics Market
